Opendata, web and dolomites

IMMOVA

Novel Immunotherapeutic Vaccine for the treatment of Alzheimer’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMOVA project word cloud

Explore the words cloud of the IMMOVA project. It provides you a very rough idea of what is the project "IMMOVA" about.

stop    administration    area    attempt    difficulties    patients    endogenous    substance    added    unknown    commercialisation    fighting    neurodegeneration    prevent    unprecedented    fraught    candidate    found    beta    disease    inherently    alzheimer    humans    therapies    peptide    immunotherapy    iia    enter    ad    strategy    isoforms    42    trial    cognitive    acquire    clinical    precludes    65    people    antigens    destroys    capability    plaques    cc    continued    thereafter    active    devastating    elderly    dire    oligomers    passive    business    senile    made    antigen    unstable    fibrous    therapeutic    aggregation    cells    market    countries    plan    context    feat    brain    guide    efforts    vaccine    primarily    delivers    strategic    afflicts    deposition    101    alz    alzinova    designed    million    trade    linked    stabilise    27    mechanisms    anti    patient    progression    bodies    ready    irreversbly    2017    families    clearance    treatments    launch    causes    efficient    exact    owns    heterogeneous    acute   

Project "IMMOVA" data sheet

The following table provides information about the project.

Coordinator
ALZINOVA AB 

Organization address
address: ERIK DAHLBERGSGATAN 11 A
city: GOTEBORG
postcode: 411 26
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.alzinova.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALZINOVA AB SE (GOTEBORG) coordinator 50˙000.00

Map

 Project objective

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain.

AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts the elderly (65), irreversbly destroys brain cells and affects the patient’s cognitive ability. The exact mechanisms leading to AD are unknown. However, it has been found that the disease is linked to the aggregation and deposition of Aβ1-42 – one of the isoforms of fibrous Aβ peptide - into senile plaques in the brain.

In recent years, significant efforts have been made to attempt targeting the clearance of Aβ1-42 through the administration of Aβ antigens (active immunotherapy) or anti-Aβ anti-bodies (passive immunotherapy). However, the development has been fraught with difficulties. Aβ1-42 oligomers are inherently unstable and heterogeneous. This precludes the development of efficient therapies.

Alzinova owns the AβCC peptide™ technology which allows for the development of a vaccine that specifically targets the endogenous substance that causes disease – a feat made possible by the unprecedented capability to stabilise the antigen. The product will be ready to enter the clinical trial in humans by the end of 2017. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation (to be included in the Phase 2 project). The strategy is to take the product to the Phase I/IIa level and thereafter acquire strategic partner for continued clinical studies and market launch.

Fighting AD is an EU-wide challenge as it affects 7.3 million people within the EU-27 countries. The effects of AD are devastating not only for the patients, but also for their families. ALZ-101 delivers in this context a strong EU-added value by its potential to stop the progression of AD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMOVA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMOVA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More